

Curriculum Vitae

Vahid Shaygannejad

Kashani Hospital, Isfahan, Iran

+983136291050 – shaygannejad@med.mui.ac.ir

0000-0002-6226-0161

PERSONAL INFORMATION

1968/01/02, Married, Two Children

EDUCATION

1996-2000, Postdoctoral Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

1985-1992, Medical Doctor (M.D.), Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

GRANTS AND FELLOWSHIPS

2008, Postdoctoral Fellow, Multiple Sclerosis Center, University of Ottawa, Canada

RESEARCH EXPERIENCE

Head of Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

TEACHING EXPERIENCE

Professor of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran

RELEVANT WORK EXPERIENCE

Head of MS Clinic in Isfahan Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

UNIVERSITY SERVICE

Professor of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran

PUBLICATIONS

Books

1. Successful living with Multiple sclerosis
2. Successful living with Devic's disease
3. Diagnosis and Treatment of Headache
4. Neurological Diseases
5. Air Pollution and Human Health

Publications

The efficacy of transdiagnostic cognitive behavioral therapy on migraine headache: a pilot, feasibility study

Forouzandeh Soleimani-Boroujeni, Negin Badihian, Shervin Badihian, Vahid Shaygannejad, Yousef Gorji. *BMC neurology* 22 (1), 1-13

2022

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

M Lefort, S Sharmin, JB Andersen, S Vukusic, R Casey, M Debouverie, G Edan, J Ciron, A Ruet, J De Sèze, E Maillart, H Zephir, P Labauge, G Defer, C Lebrun-Frenay, T Moreau, E Berger, P Clavelou, J Pelletier, B Stankoff, O Gout, E Thouvenot, O Heinzlef, A Al-Khedr, B Bourre, O Casez, P Cabre, A Montcuquet, A Wahab, JP Camdessanché, A Maurousset, H Ben Nasr, K Hankiewicz, C Pottier, N Maubeuge, D Dimitri-Boulos, C Nifle, DA Laplaud, D Horakova, EK Havrdova, R Alroughani, G Izquierdo, S Eichau, S Ozakbas, F Patti, M Onofrij, A Lugaresi, M Terzi, P Grammond, F Grand'Maison, B Yamout, A Prat, M Girard, P Duquette, C Boz, M Trojano, P McCombe, M Slee, J Lechner-Scott, R Turkoglu, P Sola, D Ferraro, F Granella, V Shaygannejad, J Prevost, D Maimone, O Skibina, K Buzzard, A Van der Walt, R Karabudak, Bart Van Wijmeersch, T Csepany, D Spitaleri, S Vucic, N Koch-Henriksen, F Sellebjerg, PS Soerensen, CC Hilt Christensen, PV Rasmussen, MB Jensen, JL Frederiksen, S Bramow, HK Mathiesen, KI Schreiber, H Butzkueven, M Magyari, T Kalincik, Emmanuelle Leray. *BMC medical research methodology* 22 (1), 1-14

2022

Effects of Acceptance and Commitment Therapy (ACT) and Mindfulness-Based Stress Reduction (MBSR) on Symptoms and Emotional Competencies in Individuals with Multiple Sclerosis

Dena Sadeghi-Bahmani, Leila Esmacili, Faezeh Mokhtari, Laleh Sadeghi, Mahshad Afsharzadeh, Vahid Shaygannejad, Omid Mirmosayyeb, Andrea N Goldstein-Piekarski, James J Gross
Multiple Sclerosis and Related Disorders, 104029

2022

Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?

A Motahharynia, S Naghavi, V Shaygannejad, I Adibi
Multiple Sclerosis and Related Disorders, 104035

2022

Assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis

2022

Mahdi Barzegar, Sepideh Allahdadian, Omid Mirmosayyeb, Reyhaneh Azarbajehani, Shervin Badihian, Nasim Nehzat, Sanaz Daryanavardi, Sabora Barzegar, Vahid Shaygannejad Psychology, Health & Medicine 27 (6), 1234-1244

Abrupt bilateral blindness as a rare post-acute demyelinating consequence of COVID-19

A Motahharynia, S Naghavi, V Shaygannejad, I Adibi

2022

Eneurologicalsci, 100411

Association of latitude and exposure to ultraviolet B radiation with severity of multiple sclerosis: an international registry study

Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Vahid Shaygannejad, Marco Onofrij, Alessandra Lugeschi, Raed Alroughani, Alexandre Prat, Catherine Larochelle, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Pierre Grammond, Helmut Butzkueven, Katherine Buzzard, Olga Skibina, Bassem I Yamout, Rana Karabudak, Oliver Gerlach, Jeannette Lechner-Scott, Davide Maimone, Roberto Bergamaschi, Vincent Van Pesch, Gerardo Iuliano, Elisabetta Cartechini, Maria José Sà, Radek Ampapa, Michael Barnett, Stella E Hughes, Cristina M Ramo-Tello, Suzanne Hodgkinson, Daniele LA Spitaleri, Thor Petersen, Ernest Gerard Butler, Mark Slee, Chris McGuigan, Pamela Ann McCombe, Franco Granella, Edgardo Cristiano, Julie Prevost, Bruce V Taylor, Josã Luis Sãnchez-Menoyo, Guy Laureys, Liesbeth Van Hijfte, Steve Vucic, Richard A Macdonell, Orla Gray, Javier Olascoaga, Norma Deri, Yara Dadalti Fragoso, Cameron Shaw, Tomas Kalincik, MSBase Study Group

2022

Neurology 98 (24), e2401-e2412

Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls

Sheida Yahyazadeh, Nafiseh Esmail, Vahid Shaygannejad, Omid Mirmosayyeb

2022

Research in Pharmaceutical Sciences 17 (3), 315

Hearing loss among patients with multiple sclerosis (PwMS): A systematic review and meta-analysis

Omid Mirmosayyeb, Mohammadjavad Naderi, Sina Raeisi, Narges Ebrahimi, Elham Moases

Ghaffary, Alireza Afshari-Safavi, Mahdi Barzegar, Vahid Shaygannejad

2022

Multiple Sclerosis and Related Disorders 62, 103754

Sexual Dysfunction in Women with Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis

2022

Omid Mirmosayyeb, Amirhossein Nafari, Ali Mahdi Hosseinabadi, Ali Malekzadeh, Majid Ghasemi, Sabora Barzegar, Rasool Mohammadi, Vahid Shaygannejad. *Sexuality and Disability* 40 (2), 381-392

The Efficacy of Transdiagnostic Cognitive Behavioral Therapy on Migraine Headache: A Randomized Clinical Trial (P15-2.002)

2022

Negin Badihian, Forouzandeh Soleimanian-Boroujeni, Shervin Badihian, Vahid Shaygannejad, Yousef Gorji. *Neurology* 98 (18 Supplement)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

Sifat Sharmin, Francesca Bovis, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Guillermo Izquierdo, Sara Eichau, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrij, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Murat Terzi, Oliver Gerlach, Raed Alroughani, Cavit Boz, Vahid Shaygannejad, Vincent van Pesch, Elisabetta Cartechini, Ludwig Kappos, Jeannette Lechner-Scott, Roberto Bergamaschi, Recai Turkoglu, Claudio Solaro, Gerardo Iuliano, Franco Granella, Bart Van Wijmeersch, Daniele Spitaleri, Mark Slee, Pamela McCombe, Julie Prevost, Radek Ampapa, Serkan Ozakbas, Jose Luis Sanchez-Menoyo, Aysun Soysal, Steve Vucic, Thor Petersen, Koen de Gans, Ernest Butler, Suzanne Hodgkinson, Youssef Sidhom, Riadh Gouider, Edgardo Cristiano, Tamara Castillo-Triviño, Maria Laura Saladino, Michael Barnett, Fraser Moore, Csilla Rozsa, Bassem Yamout, Olga Skibina, Anneke van der Walt, Katherine Buzzard, Orla Gray, Stella Hughes, Angel Perez Sempere, Bhim Singhal, Yara Fragoso, Cameron Shaw, Allan Kermode, Bruce Taylor, Magdolna Simo, Neil Shuey, Talal Al-Harbi, Richard Macdonell, Jose Andres Dominguez, Tunde Csepany, Carmen Adella Sirbu, Maria Pia Sormani, Helmut Butzkueven, Tomas Kalincik. *European Journal of Neurology*

2022

Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity

Aryan Kavosh, Fereshteh Ashtari, Saba Naghavi, Iman Adibi, Vahid Shaygannejad, Zahra Karimi, Sina Arabi, Maryam Rahimi, Shahbanoo Mazaheri. *Multiple Sclerosis and Related Disorders* 61, 103708

Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis

Omid Mirmosayyeb, Narges Ebrahimi, Mahdi Barzegar, Alireza Afshari-Safavi, Sara Bagherieh, Vahid Shaygannejad. *PloS one* 17 (4), e0266492

2022

The Role of Cobalamin on Interleukin 10, Osteopontin, and Related MicroRNAs in Multiple Sclerosis

2022

Mohammad Sadegh Hesamian, Vahid Shaygannejad, Marjan Golabi, Omid Mirmosayyeb, Alireza Andalib, Nahid Eskandari. Iranian Journal of Allergy, Asthma and Immunology, 1-12

Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS
omas Kalincik, Ilya Kister, Tamar E Bacon, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala-Havrdova, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Marco Onofrij, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Cavit Boz, Francois Grand'Maison, Roberto Bergamaschi, Oliver Gerlach, Maria J Sa, Ludwig Kappos, Elisabetta Cartechini, Jeannette Lechner-Scott, Vincent van Pesch, Vahid Shaygannejad, Franco Granella, Daniele Spitaleri, Gerardo Iuliano, Davide Maimone, Julie Prevost, Aysun Soysal, Recai Turkoglu, Radek Ampapa, Helmut Butzkueven, Gary Cutter, MSBase Study Group. Multiple Sclerosis Journal, 13524585221084577 2022

Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review 2022
Omid Mirmosayyeb, Elham Moases Ghaffary, Sara Bagherieh, Mahdi Barzegar, Mohammad Sadegh Dehghan, Vahid Shaygannejad. Multiple Sclerosis and Related Disorders 60, 103697

Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult. 2022
Ziaei A, Garcia-Miralles M, Radulescu CI, Sidik H, Silvin A, Bae HG, Bonnard C, Yusof NABM, Ferrari Bardile C, Tan LJ, Ng AYJ, Tohari S, Dehghani L, Henry L, Yeo XY, Lee S, Venkatesh B, Langley SR, Shaygannejad V, Reversade B, Jung S, Ginhoux F, Pouladi MA. Brain Pathol. 2022 Mar 13:e13064. doi: 10.1111/bpa.13064. Online ahead of print.

Radiologically Isolated Syndrome: An Atypical Presentation of Balo's Concentric Sclerosis in a Patient with the Meniere's Disease. 2022
Nouri H, Mirmosayyeb O, Badihian S, Shaygannejad V. Neurol India. 2022 Jan-Feb;70(1):439-440. doi: 10.4103/0028-3886.338680.

Bell's palsy after Sputnik V COVID-19 (Gam-COVID-Vac) vaccination. 2022
Mirmosayyeb O, Barzegar M, Rezaei M, Baharlouie N, Shaygannejad V. Clin Case Rep. 2022 Feb 23;10(2):e05468. doi: 10.1002/ccr3.5468. eCollection 2022 Feb.

Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. 2022
Askari M, Mirmosayyeb O, Ghaffary EM, Ghoshouni H, Shaygannejad V, Ghajarzadeh M. Mult Scler Relat Disord. 2022 Feb 9;59:103680. doi: 10.1016/j.msard.2022.103680. Online ahead of print.

- Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset. 2022
Sadeghi-Bahmani D, Barzegar M, Mirmosayyeb O, Vaheb S, Nehzat N, Shaygannejad V, Brand S.J
Clin Med. 2022 Jan 29;11(3):734. doi: 10.3390/jcm11030734.
-
- COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. 2022
Barzegar M, Mirmosayyeb O, Ebrahimi N, Bagherieh S, Afshari-Safavi A, Hosseinabadi
AM, Shaygannejad V, Asgari N. Mult Scler Relat Disord. 2022 Jan;57:103359. doi:
10.1016/j.msard.2021.103359. Epub 2021 Nov 1.
-
- COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021. 2022
Naghavi S, Kavosh A, Adibi I, Shaygannejad V, Arabi S, Rahimi M, Mazaheri S, Ashtari F. Mult Scler
Relat Disord. 2022 Jan;57:103335. doi: 10.1016/j.msard.2021.103335. Epub 2021 Oct 16.
-
- Incidence, prevalence, and characteristics of heart failure among patients with multiple sclerosis: A systematic review and meta-analysis. 2022
Bagherieh S, Ghoshouni H, Bostan F, Afshari-Safavi A, Badihian S, Barzegar M, Shaygannejad V,
Mirmosayyeb O. Mult Scler Relat Disord. 2022 Feb 4;59:103665. doi: 10.1016/j.msard.2022.103665.
Online ahead of print.
-
- Comparison of susceptibility weighted imaging with conventional MRI sequences in multiple sclerosis plaque assessment: A cross-sectional study. 2021
Rabbani M, Shaygannejad V, Bahrami M, Badii S. J Res Med Sci. 2021 Dec 22;26:128. doi:
10.4103/jrms.JRMS_726_17. eCollection 2021.
-
- Prevalence of trigeminal neuralgia in multiple sclerosis: A systematic review and meta-analysis. 2021
Houshi S, Tavallaei MJ, Barzegar M, Afshari-Safavi A, Vaheb S, Mirmosayyeb O, Shaygannejad
V. Mult Scler Relat Disord. 2022 Jan;57:103472. doi: 10.1016/j.msard.2021.103472. Epub 2021 Dec
29.
-
- The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica. 2021
Moayednia M, Dehghani L, Safi A, Shaygannejad V, Sohrabi K, Rezvani M, Akrami MR, Soghrati
M, Aboutalebi MM, Barzegar M. Basic Clin Neurosci. 2021 Mar-Apr;12(2):199-204. doi:
10.32598/bcn.12.2.1009.2. Epub 2021 Mar 1.

- The Effect of Emotional Freedom Technique on Fatigue among Women with Multiple Sclerosis: A Randomized Controlled Trial. 2021
Ghaderi Z, Nazari F, Shaygannejad V. *Iran J Nurs Midwifery Res.* 2021 Oct 22;26(6):531-536. doi: 10.4103/ijnmr.IJNMR_188_19. eCollection 2021 Nov-Dec.
-
- Characteristics of COVID-19 in patients with multiple sclerosis. 2021
Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi Langroodi H, Baghbanian SM, Mozhdehipanah H, Majdi-Nasab N, Hosseini S, Poursadeghfard M, Beladimoghadam N, Razazian N, Ayoubi S, Rezaeimanesh N, Eskandarieh S, Naser Moghadasi A. *Mult Scler Relat Disord.* 2022 Jan;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30.
-
- The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients. 2021
Karimi L, Eskandari N, Shaygannejad V. *Neuroimmunomodulation.* 2021 Nov 22:1-9. doi: 10.1159/000519777. Online ahead of print.
-
- Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis. 2021
Mirmosayyeb O, Shaygannejad V, Bagherieh S, Hosseinabadi AM, Ghajarzadeh M. *Neurol Sci.* 2022 Jan;43(1):233-241. doi: 10.1007/s10072-021-05750-w. Epub 2021 Nov 17.
-
- Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study. 2021
Seyed Ahadi M, Sahraian MA, Shaygannejad V, Anjidani N, Mohammadiani Nejad SE, Beladi Moghadam N, Ayromlou H, Yousefi Pour GA, Yazdanbakhsh S, Jafari M, Naser Moghadasi A. *Caspian J Intern Med.* 2021;12(Suppl 2):S491-S494. doi: 10.22088/cjim.12.0.491.
-
- Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. 2021
De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrij M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. *Comput Methods Programs Biomed.* 2022 Jan;213:106479. doi: 10.1016/j.cmpb.2021.106479. Epub 2021 Nov 5.
-
- Managing anxiety among multiple sclerosis patients during COVID-19 pandemic. 2021

Adibi I, Mirmosayyeb O, Ramezani N, Shaygannejad V.J Res Med Sci. 2021 Aug 30;26:68. doi: 10.4103/jrms.JRMS_633_20. eCollection 2021.

Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report.

2021

Mirmosayyeb O, Bagherieh S, Shaygannejad V.Hum Vaccin Immunother. 2021 Nov 2;17(11):4099-4101. doi: 10.1080/21645515.2021.1971920. Epub 2021 Oct 29.

The prevalence of Myocardial Infarction among Multiple Sclerosis Patients: a Systematic Review and Meta-analysis.

Tavallaei MJ, Tavallaei AH, Ebrahimi N, Ghoshoumi H, Afshari-Safavi A, Badihian S, Shaygannejad V, Mirmosayyeb O.Mult Scler Relat Disord. 2021 Nov;56:103292. doi: 10.1016/j.msard.2021.103292. Epub 2021 Sep 30.

Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis.

2021

Imani SZH, Hojati Z, Khalilian S, Dehghanian F, Kheirollahi M, Khorrani M, Shaygannejad V, Mirmosayyeb O.Sci Rep. 2021 Sep 28;11(1):19260. doi: 10.1038/s41598-021-98691-5.

Paraparesis due to aortic thromboembolism as a rare complication of COVID-19 infection.

Motahharynia A, Naghavi S, Shaygannejad V, Adibi I.J Vasc Surg. 2021 Sep;74(3):1047. doi: 10.1016/j.jvs.2021.04.062.

2021

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.

2021

Nehzat N, Mirmosayyeb O, Barzegar M, Vosoughi R, Fazeli E, Shaygannejad V.Neurol Res Int. 2021 Jul 15;2021:6679197. doi: 10.1155/2021/6679197. eCollection 2021.

Quantitative Magnetic Resonance Imaging Analysis of Early Markers of Upper Cervical Cord Atrophy in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

2021

Adibi I, Najafi A, Merajifar F, Ramezani N, Nouri H, Jalilvand N, Ashtari F, Vard A, Shaygannejad V.Mult Scler Int. 2021 Jul 9;2021:9917582. doi: 10.1155/2021/9917582. eCollection 2021.

Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS).

2021

Mirmosayyeb O, Barzegar M, Afshari-Safavi A, Nehzat N, Heidari A, Emami P, Shaygannejad V.Mult Scler Int. 2021 Jun 10;2021:8874999. doi: 10.1155/2021/8874999. eCollection 2021.

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.

Doosti R, Naser Moghadasi A, Azimi AR, Karbalai Saleh S, Etemadifar M, Shaygannejad V, Ashtari F, Harirchian MH, Siroos SB, Ayramloo H, Majdinasab N, Hojjati SMM, Asghari N, Baghbanian SM, Cheraghmakani H, Abedini M, Sedighi B, Mohseni Abbas Abadi N, Ghasemitabar M, Talebianpour S, Babayi Daylari T, Dana V, Ghaleh Noie N, Sahraian MA. *Caspian J Intern Med.* 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263. 2021

Early predictors of conversion to secondary progressive multiple sclerosis.

Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, Mirmosayyeb O, Shaygannejad V. *Mult Scler Relat Disord.* 2021 Sep;54:103115. doi: 10.1016/j.msard.2021.103115. Epub 2021 Jun 26. 2021

Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018.

Moradi N, Sharmin S, Malpas C, Ozakbas S, Shaygannejad V, Terzi M, Boz C, Yamout B, Turkoglu R, Karabudak R, Hamdy S, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T; MSBase Study Group. *CNS Drugs.* 2021 Oct;35(10):1097-1106. doi: 10.1007/s40263-021-00833-w. Epub 2021 Jun 23. 2021

Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression.

De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrij M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, José Sá M, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. *Comput Methods Programs Biomed.* 2021 Sep;208:106180. doi: 10.1016/j.cmpb.2021.106180. Epub 2021 May 18.

Association of Exposure to Particulate Matters and Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Lotfi F, Mansourian M, Mirmoayyeb O, Najdaghi S, Shaygannejad V, Esmacil N. *Neuroimmunomodulation.* 2022;29(1):21-27. doi: 10.1159/000516559. Epub 2021 Jun 16. 2021

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.

Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrij M, 2021

Lugaresi A, Terzi M, Grammond P, Grand Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Leray E, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. *Mult Scler Relat Disord*. 2021 Aug;53:103012. doi: 10.1016/j.msard.2021.103012. Epub 2021 May 8.

Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Mirmosayyeb O, Shaygannejad V, Nehzat N, Mohammadi A, Ghajarzadeh M. *Int J Prev Med*. 2021 Feb 24;12:14. doi: 10.4103/ijpvm.IJPVM_75_20. eCollection 2021.

2021

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.

Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. *Neurol Neuroimmunol Neuroinflamm*. 2021 May 20;8(4):e1001. doi: 10.1212/NXI.0000000000001001. Print 2021 Jul.

2021

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.

Barzegar M, Vaheb S, Mirmosayyeb O, Afshari-Safavi A, Nehzat N, Shaygannejad V. *Mult Scler Relat Disord*. 2021 Jul;52:102947. doi: 10.1016/j.msard.2021.102947. Epub 2021 Apr 11.

Mizaj assessment in Multiple Sclerosis (MS) patients based on Persian Medicine.

Abbasian R, Mojahedi M, Alizadeh M, Khafri S, Ansaripour M, Moosavyzadeh A, Kamali M, Babaeian M, Sourtiji H, Shaygannejad V, Kerdarian H, Rezaeizadeh H. *J Complement Integr Med*. 2021 May 10. doi: 10.1515/jcim-2020-0428. Online ahead of print.

2021

Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial.

Abbasirad F, Shaygannejad V, Hosseininiasab F, Mirmosayyeb O, Mahaki B, Moayedi B, Esmaeil N. *Int Immunopharmacol*. 2021 Aug;97:107715. doi: 10.1016/j.intimp.2021.107715. Epub 2021 Apr 29.

2021

Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage.

2021

Shaygannejad V, Mirmosayyeb O, Nehzat N, Ghajarzadeh M. *Neurol Sci.* 2021 Jul;42(7):2615-2618. doi: 10.1007/s10072-021-05253-8. Epub 2021 Apr 15.

Gene expression profiles of YAP1, TAZ, CRB3, and VDR in familial and sporadic multiple sclerosis among an Iranian population.

Khalilian S, Hojati Z, Dehghanian F, Shaygannejad V, Imani SZH, Kheirollahi M, Khorrami M, Mirmosayyeb O. *Sci Rep.* 2021 Apr 8;11(1):7713. doi: 10.1038/s41598-021-87131-z.

2021

Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis.

Barzegar M, Mirmosayyeb O, Rezaei M, Bjørklund G, Nehzat N, Afshari-Safavi A, Shaygannejad V. *Dysphagia.* 2022 Feb;37(1):21-27. doi: 10.1007/s00455-021-10245-z. Epub 2021 Feb 12.

2021

Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.

Karimi L, Eskandari N, Shaygannejad V, Zare N, Andalib A, Khanahmad H, Mirmosayyeb O. *Iran J Allergy Asthma Immunol.* 2020 Aug 25;19(4):416-425. doi: 10.18502/ijai.v19i4.4116.

2020

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand'Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermode A, Csepany T, Singhal B, Shuey N, Pirotska I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study Group. *Neurology.* 2021 Feb 2;96(5):e783-e797. doi: 10.1212/WNL.0000000000011242. Epub 2020 Dec 28.

2020

Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.

Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M. *Autoimmun Rev.* 2021 Feb;20(2):102727. doi: 10.1016/j.autrev.2020.102727. Epub 2020 Dec 17.

2020

Pregnancy outcome in patients with multiple sclerosis treated with Rituximab: A case-series study.

Seyed Ahadi M, Sahraian MA, Baghbanian SM, Azimi A, Shaygannejad V, Anjidani N, Mohammadiani Nejad SE, Izadi S, Beladi Moghadam N, Ayromlou H, Ashtari F, Amiri A, Niknam

2020

Z, Asarzadegan F, Mazdeh M, Bayati A, Yousefi Pour GA, Yazdanbakhsh S, Naser Moghadasi A. *Mult Scler Relat Disord.* 2021 Jan;47:102667. doi: 10.1016/j.msard.2020.102667. Epub 2020 Dec 4.

Frequency of comorbidities in Neuromyelitis Optica spectrum disorder.

Barzegar M, Mirmosayyeb O, Nehzat N, Vaheb S, Shaygannejad V, Asgari N. *Mult Scler Relat Disord.* 2021 Feb;48:102685. doi: 10.1016/j.msard.2020.102685. Epub 2020 Dec 9. 2020

Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients.

Shahpouri MM, Berekatain M, Tavakoli M, Mirmosayyeb O, Safaei A, Shaygannejad V. *Neurol Res Int.* 2020 Nov 22;2020:8874424. doi: 10.1155/2020/8874424. eCollection 2020. 2020

Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis.

Barzegar M, Allahdadian S, Mirmosayyeb O, Azarbajejani R, Badihian S, Nehzat N, Daryanavardi S, Barzegar S, Shaygannejad V. *Psychol Health Med.* 2020 Dec 10:1-11. doi: 10.1080/13548506.2020.1859564. Online ahead of print. 2020

Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.

Shaygannejad V, Afshari-Safavi A, Hatf B. *Neurol Sci.* 2021 Jul;42(7):2891-2901. doi: 10.1007/s10072-020-04905-5. Epub 2020 Nov 20. 2020

Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD).

Barzegar M, Sadeghi Bahmani D, Mirmosayyeb O, Azarbajejani R, Afshari-Safavi A, Vaheb S, Nehzat N, Dana A, Shaygannejad V, Motl RW, Brand S. *J Clin Med.* 2020 Nov 9;9(11):3604. doi: 10.3390/jcm9113604. 2020

The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis.

Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. *J Clin Neurosci.* 2020 Sep;79:33-38. doi: 10.1016/j.jocn.2020.06.021. Epub 2020 Aug 4. 2020

MS Care in Novel Coronavirus 19 Pandemic.

Ramezani N, Adibi I, Mirmosayyeb O, Shaygannejad V. *Int J Prev Med.* 2020 Jul 9;11:98. doi: 10.4103/ijpvm.IJPVM_242_20. eCollection 2020. 2020

Screening neuromyelitis optica patients for COVID-19 infection.

Mirmosayyeb O, Vaheb S, Barzegar M, Shaygannejad V, Bonavita S, Ghajarzadeh M. *Autoimmun Rev.* 2020 Nov;19(11):102669. doi: 10.1016/j.autrev.2020.102669. Epub 2020 Sep 14. 2020

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.

Cheshmavar M, Mirmosayyeb O, Badihian N, Badihian S, Shaygannejad V. *Acta Neurol Scand.* 2021 Feb;143(2):178-187. doi: 10.1111/ane.13344. Epub 2020 Oct 27. 2020

Upregulation of MTOR, RPS6KB1, and EIF4EBP1 in the whole blood samples of Iranian patients with multiple sclerosis compared to healthy controls.

Akbarian F, Tabatabaiefar MA, Shaygannejad V, Shahpouri MM, Badihian N, Sajjadi R, Dabiri A, Jalilian N, Noori-Dalooi MR. *Metab Brain Dis.* 2020 Dec;35(8):1309-1316. doi: 10.1007/s11011-020-00590-7. Epub 2020 Aug 18. 2020

Comparison of Psychological Difficulties in Patients with Migraine and Epilepsy Using PARADISE-24 Questionnaire.

Mirmosayyeb O, Shaygannejad V, Ghajarzadeh M. *J Multidiscip Healthc.* 2020 Jul 10;13:609-613. doi: 10.2147/JMDH.S260056. eCollection 2020. 2020

Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial.

Shahpouri MM, Barekatain M, Tavakoli M, Badihian S, Shaygannejad V. *Int J Prev Med.* 2020 Jun 19;11:69. doi: 10.4103/ijpvm.IJPVM_154_19. eCollection 2020. 2020

Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

Sadeghpour N, Mirmosayyeb O, Bjørklund G, Shaygannejad V. *J Mol Neurosci.* 2020 Nov;70(11):1829-1835. doi: 10.1007/s12031-020-01576-x. Epub 2020 Aug 1. 2020

Characteristics of COVID-19 disease in multiple sclerosis patients.

Barzegar M, Mirmosayyeb O, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, Vosoughi R. *Mult Scler Relat Disord.* 2020 Oct;45:102276. doi: 10.1016/j.msard.2020.102276. Epub 2020 Jun 8. 2020

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.

Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Laroche C, Alroughani R, Bergamaschi R, Sola P, 2020

Ferraro D, Grammond P, Grand' Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T. *Mult Scler*. 2021 Apr;27(5):755-766. doi: 10.1177/1352458520926955. Epub 2020 Jun 15.

Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder. Ashtari F, Mehdipour R, Shaygannejad V, Asgari N. *Mult Scler Relat Disord*. 2020 Sep;44:102252. 2020 doi: 10.1016/j.msard.2020.102252. Epub 2020 Jun 2.

Quality of life among patients with multiple sclerosis and voiding dysfunction: a cross-sectional study. Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. *BMC Urol*. 2020 Jun 3;20(1):62. doi: 10.1186/s12894-020-00590-w. 2020

Spiritual health in women with multiple sclerosis and its association with self-esteem. Shaygannejad V, Mohamadirizi S. *J Educ Health Promot*. 2020 Mar 31;9:64. doi: 10.4103/jehp.jehp_144_19. eCollection 2020. 2020

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. *Mult Scler Relat Disord*. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23. 2020

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, Shaygannejad V. *Neurol Neuroimmunol Neuroinflamm*. 2020 May 5;7(4):e753. doi: 10.1212/NXI.0000000000000753. Print 2020 Jul. 2020

Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. Mirmosayyeb O, Brand S, Barzegar M, Afshari-Safavi A, Nehzat N, Shaygannejad V, Sadeghi Bahmani DJ. *Clin Med*. 2020 May 2;9(5):1326. doi: 10.3390/jcm9051326. 2020

Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. 2020

AlSharoqi IA, Aljumah M, Bohlega S, Boz C, Daif A, El-Koussa S, Inshasi J, Kurtuncu M, Müller T, Retief C, Sahraian MA, Shaygannejad V, Slassi I, Taha K, Zakaria M, Sørensen PS. *Neurol Ther.* 2020 Jun;9(1):55-66. doi: 10.1007/s40120-020-00187-3. Epub 2020 Apr 15.

Comparison of prevalence rates of restless legs syndrome, self-assessed risks of obstructive sleep apnea, and daytime sleepiness among patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) and Neuromyelitis Optica Spectrum Disorder (NMOSD). 2020
Shaygannejad V, Sadeghi Bahmani D, Soleimani P, Mirmosayyeb O, Barzegar M, Amra B, Brand S. *Sleep Med.* 2020 Jun;70:97-105. doi: 10.1016/j.sleep.2019.11.1266. Epub 2019 Dec 17.

Evaluation of glucose-6-phosphate dehydrogenase serum level in patients with multiple sclerosis and neuromyelitis optica. 2020
Chitsaz N, Dehghani L, Safi A, Esmalian-Afyouni N, Shaygannejad V, Rezvani M, Sohrabi K, Moridi K, Moayednia M. *Iran J Neurol.* 2019 Oct 7;18(4):150-153.

Modulation of Th17 Proliferation and IL-17A Gene Expression by Acetylated Form of Apigenin in Patients with Multiple Sclerosis. 2020
Rahmati M, Ghannadian SM, Kasiri N, Ahmadi L, Motedayyen H, Shaygannejad V, Pourazar A, Alsahebfosoul F, Ganjalikhani Hakemi M, Eskandari N. *Immunol Invest.* 2021 Feb;50(2-3):216-229. doi: 10.1080/08820139.2020.1726381. Epub 2020 Feb 26.

Sexual dysfunction in women with multiple sclerosis: prevalence and impact on quality of life. 2020
Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. *BMC Urol.* 2020 Feb 21;20(1):15. doi: 10.1186/s12894-020-0581-2.

Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects. 2020
Ashtari F, Madanian R, Shaygannejad V, Zarkesh SH, Ghadimi K. *Int J Physiol Pathophysiol Pharmacol.* 2019 Dec 15;11(6):267-273. eCollection 2019.

The prevalence of lower urinary tract symptoms based on individual and clinical parameters in patients with multiple sclerosis. 2020
Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. *BMC Neurol.* 2020 Jan 17;20(1):24. doi: 10.1186/s12883-019-1582-1.

Evaluation of cognitive rehabilitation on the cognitive performance in multiple sclerosis: A randomized controlled trial. 2020

Shahpouri MM, Barekatin M, Tavakoli M, Sanaei S, Shaygannejad V. *J Res Med Sci.* 2019 Dec 23;24:110. doi: 10.4103/jrms.JRMS_124_19. eCollection 2019.

Therapeutic plasma exchange may adjust IL-6 and TGF- β signals in relapsed MS patients peripheral blood.

Jamshidian A, Abd-Nikfarjam B, Khademi Z, Shaygannejad V, Salehi M. *J Clin Apher.* 2020 Apr;35(2):72-78. doi: 10.1002/jca.21755. Epub 2020 Jan 3.

2020

Association Study between Functional Polymorphisms of *MMP9* Gene Promoter and Multiple Sclerosis Susceptibility in an Iranian Population.

Sabbagh S, Nadeali Z, Dehghani L, Shaygannejad V, Rezvani M, Saboori M, Ganji H, Tahani S, Dehghani F, Hosseinzadeh S, Marzbani E, Shafiei P. *Iran J Public Health.* 2019 Sep;48(9):1697-1703.

2019

Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.

Fattahi M, Eskandari N, Sotoodehnejadnematalahi F, Shaygannejad V, Kazemi M. *Cell J.* 2020 Apr;22(1):92-95. doi: 10.22074/cellj.2020.6486. Epub 2019 Sep 8.

2019

Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients.

Tahani S, Dehghani L, Jahanbani-Ardakani H, Shaygannejad V, Fazli A, Hamidavi A, Eskandari N. *J Immunoassay Immunochem.* 2019;40(5):555-563. doi: 10.1080/15321819.2019.1655649. Epub 2019 Aug 19.

2019

MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.

Fattahi M, Rezaei N, Nematalahi FS, Shaygannejad V, Fouladi S, Karimi L, Fathi F, Dehghani L, Mirmosayyeb O, Eskandari N. *Mult Scler Relat Disord.* 2019 Oct;35:241-245. doi: 10.1016/j.msard.2019.07.034. Epub 2019 Jul 31.

2019

Novel mutation in *HTRAI* in a family with diffuse white matter lesions and inflammatory features.

Ziaei A, Xu X, Dehghani L, Bonnard C, Zellner A, Jin Ng AY, Tohari S, Venkatesh B, Haffner C, Reversade B, Shaygannejad V, Pouladi MA. *Neurol Genet.* 2019 Jul 8;5(4):e345. doi: 10.1212/NXG.0000000000000345. eCollection 2019 Aug.

2019

Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.

Ashtari F, Mehdipour R, Shaygannejad V, Mansourian M. *Mult Scler Relat Disord.* 2019 Sep;34:77-82. doi: 10.1016/j.msard.2019.06.013. Epub 2019 Jun 20.

2019

- Management of seizures in patients with multiple sclerosis; an Iranian consensus.
Asadi-Pooya AA, Sahraian MA, Sina F, Baghbanian SM, Habibabadi JM, Shaygannejad V, Asadollahi M, Karvigh SA, Moghadasi AN, Nikseresht A, Motamedi M. *Epilepsy Behav.* 2019 Jul;96:244-248. doi: 10.1016/j.yebeh.2019.04.032. 2019
-
- In Patients With Multiple Sclerosis, Both Objective and Subjective Sleep, Depression, Fatigue, and Paresthesia Improved After 3 Weeks of Regular Exercise.
Sadeghi Bahmani D, Kesselring J, Papadimitriou M, Bansi J, Pühse U, Gerber M, Shaygannejad V, Holsboer-Trachsler E, Brand S. *Front Psychiatry.* 2019 May 3;10:265. doi: 10.3389/fpsy.2019.00265. eCollection 2019. 2019
-
- Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls.
Barzegar M, Sadeghi Bahmani D, Nehzat N, Kiani M, Hashemi N, Mirmosayyeb O, Brand S, Shaygannejad V. *Mult Scler Relat Disord.* 2019 Jul;32:81-87. doi: 10.1016/j.msard.2019.04.008. Epub 2019 Apr 12. 2019
-
- Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients.
Alidadiani P, Eskandari N, Shaygannejad V, Dabiri A, Manian M, Jahanbani-Ardakani H, Mirmosayyeb O. *Biomol Concepts.* 2019 Apr 11;10(1):62-67. doi: 10.1515/bmc-2019-0007. 2019
-
- Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (MS) Patients In Vitro.
Shariati M, Shaygannejad V, Abbasirad F, Hosseinasab F, Kazemi M, Mirmosayyeb O, Esmacil N. *Inflammation.* 2019 Aug;42(4):1203-1214. doi: 10.1007/s10753-019-00980-9. 2019
-
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JW, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slesne M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. *JAMA.* 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. 2019
-
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrij M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz 2019

C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven HJ *Neurol Neurosurg Psychiatry*. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

Genetic Variation in Intergenic and Exonic miRNA Sequence and Risk of Multiple Sclerosis in the Isfahan Patients.

Golshani Z, Hojati Z, Sharifzadeh A, Shaygannejad V, Jafarina M. *Iran J Allergy Asthma Immunol*. 2018 Oct 14;17(5):477-484.

2018

Promising effect of rapamycin on multiple sclerosis.

Bagherpour B, Salehi M, Jafari R, Bagheri A, Kiani-Esfahani A, Edalati M, Kardi MT, Shaygannejad V. *Mult Scler Relat Disord*. 2018 Nov;26:40-45. doi: 10.1016/j.msard.2018.08.009. Epub 2018 Aug 10.

2018

The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder.

Mehdipour-Dastjerdi R, Ashtari F, Shaygannejad V, Mansourian M, Safaei A. *Iran J Neurol*. 2018 Apr 4;17(2):58-63.

2018

Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran.

Salari M, Mirmosayyeb O, Etemadifar M, Shaygannejad V, Khorvash F, Najafi MR, Ashtari F, Chitsaz A. *Iran J Neurol*. 2018 Jan 5;17(1):6-10.

2018

Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated from Newly Diagnosed and IFN- β 1b-Treated MS Patients.

Navabi F, Shaygannejad V, Abbasirad F, Vaez E, Hosseininasab F, Kazemi M, Mirmosayyeb O, Alsahebhosoul F, Esmail N. *Inflammation*. 2019 Feb;42(1):54-63. doi: 10.1007/s10753-018-0872-x.

2018

Association between Sun Exposure, Vitamin D Intake, Serum Vitamin D Level, and Immunoglobulin G Level in Patients with Neuromyelitis Optica Spectrum Disorder.

Shaygannejad V, Maljaei MB, Bank SS, Mirmosayyeb O, Maracy MR, Askari G. *Int J Prev Med*. 2018 Aug 14;9:68. doi: 10.4103/ijpvm.IJPVM_45_16. eCollection 2018.

2018

Lower extremity deep venous thrombosis in a multiple sclerosis patient on dimethyl fumarate.

Mirmosayyeb O, Fayyazi E, Shaygannejad V, Esmail N. *Mult Scler Relat Disord*. 2018 Oct;25:196. doi: 10.1016/j.msard.2018.07.037. Epub 2018 Jul 21.

2018

- Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group. *JAMA Neurol.* 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109. 2018
-
- High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy.
Robat-Jazi B, Hosseini M, Shaygannejad V, Nafissi S, Rezaei A, Mansourain M, Mirmosayyeb O, Esmacil N. *Neuroimmunomodulation.* 2018;25(2):80-88. doi: 10.1159/000490855. Epub 2018 Aug 2. 2018
-
- Neuromyelitis optica spectrum disorder and menstruation.
Badihian S, Manouchehri N, Mirmosayyeb O, Ashtari F, Shaygannejad V. *Rev Neurol (Paris).* 2018 Dec;174(10):716-721. doi: 10.1016/j.neurol.2018.01.373. Epub 2018 Jul 23. 2018
-
- Stability of Mental Toughness, Sleep Disturbances, and Physical Activity in Patients With Multiple Sclerosis (MS)-A Longitudinal and Pilot Study.
Sadeghi Bahmani D, Esmacili L, Shaygannejad V, Gerber M, Kesselring J, Lang UE, Holsboer-Trachsler E, Brand S. *Front Psychiatry.* 2018 May 17;9:182. doi: 10.3389/fpsy.2018.00182. eCollection 2018. 2018
-
- Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran.
Barzegar M, Badihian S, Mirmosayyeb O, Ashtari F, Jamadi M, Emami S, Jahani L, Safavi A, Shaygannejad V. *Mult Scler Relat Disord.* 2018 May;22:161-165. doi: 10.1016/j.msard.2018.04.009. Epub 2018 Apr 14. 2018
-
- OX40 Gene and Serum Protein Expression Profiles in Patients with Parkinson's Disease.
Seyedjoodaki A, Alsahebhosoul F, Eskandari N, Shaygannejad V, Salehi M, Kazemi M, Manian M, Mirmosayyeb O, Taghi Kardi M. *Cell J.* 2018 Jul;20(2):177-182. doi: 10.22074/cellj.2018.5038. Epub 2018 Mar 18. 2018
-
- The interplay of multiple sclerosis and menstrual cycle: Which one affects the other one? 2018

Mirmosayyeb O, Badihian S, Manouchehri N, Basiri AK, Barzegar M, Esmail N, Fayyazi E, Shaygannejad V. *Mult Scler Relat Disord*. 2018 Apr;21:46-50. doi: 10.1016/j.msard.2018.01.020. Epub 2018 Feb 2.

Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis.

Hosseini M, Robat-Jazi B, Shaygannejad V, Naffisi S, Mirmosayyeb O, Rezaei A, Mansourian M, Esmail N. *Neuroimmunomodulation*. 2017;24(4-5):264-270. doi: 10.1159/000486037. Epub 2018 Feb 8. 2018

Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.

Manouchehri N, Mirmosayyeb O, Badihian S, Shaygannejad V. *Mult Scler Relat Disord*. 2018 Jan;19:121-123. doi: 10.1016/j.msard.2017.11.012. Epub 2017 Nov 22. 2018

The Effect of Emotional Intelligence Training on Self-efficacy in Women with Multiple Sclerosis.

Mehrabi Z, Nazari F, Mehrabi T, Shaygannejad V. *Iran J Nurs Midwifery Res*. 2017 Nov-Dec;22(6):421-426. doi: 10.4103/ijnmr.IJNMR_145_16. 2017

Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations.

Sahraian MA, Moghadasi AN, Azimi AR, Asgari N, H Akhoundi F, Abolfazli R, Alaie S, Ashtari F, Ayromlou H, Baghbanian SM, Moghadam NB, Fatehi F, Foroughipour M, Langroodi HG, Majdinasab N, Nickseresht A, Nourian A, Shaygannejad V, Torabi HR. *Mult Scler Relat Disord*. 2017 Nov;18:144-151. doi: 10.1016/j.msard.2017.09.015. Epub 2017 Sep 25. 2017

Evaluating the effect of adding Fish oil to Fingolimod on TNF- α , IL1 β , IL6, and IFN- γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial.

Zandi-Esfahan S, Fazeli M, Shaygannejad V, Hasheminia J, Badihian S, Aghayerashti M, Maghzi H. *Clin Neurol Neurosurg*. 2017 Dec;163:173-178. doi: 10.1016/j.clineuro.2017.10.004. Epub 2017 Oct 3. 2017

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett 2017

M, Hillert J, Butzkueven H; MSBase Study Group. *Brain*. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.

Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. *J Neurol*. 2017 Sep;264(9):2003-2009. doi: 10.1007/s00415-017-8590-0. Epub 2017 Aug 22.

2017

A comparison the effects of reflexology and relaxation on the psychological symptoms in women with multiple sclerosis.

Soheili M, Nazari F, Shaygannejad V, Valiani M. *J Educ Health Promot*. 2017 Apr 19;6:11. doi: 10.4103/jehp.jehp_166_14. eCollection 2017.

2017

The effect of electronic education on knowledge of patients with multiple sclerosis.

Mohamadirizi S, Shaygannejad V, Mohamadirizi S, Tolou-Ghamari Z. *J Educ Health Promot*. 2017 Apr 19;6:10. doi: 10.4103/jehp.jehp_144_14. eCollection 2017.

2017

The survey of mindfulness in multiple sclerosis patients and its association with attachment style.

Mohamadirizi S, Shaygannejad V, Mohamadirizi S. *J Educ Health Promot*. 2017 Apr 19;6:7. doi: 10.4103/jehp.jehp_114_14. eCollection 2017.

2017

Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study.

Ashtari F, Safaei A, Shaygannejad V, Najafi MA, Vesal S. *J Res Med Sci*. 2017 Mar 15;22:41. doi: 10.4103/1735-1995.202142. eCollection 2017.

2017

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. *Ann Neurol*. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

2017

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V,

2017

Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M. *Mult Scler*. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

Consanguinity and multiple sclerosis susceptibility: A case control study.

Maghzi H, Shaygannejad V, Minagar A, Hassanzadeh A, Maghzi AH. *Mult Scler Relat Disord*. 2016 Nov;10:179-180. doi: 10.1016/j.msard.2016.09.013. Epub 2016 Sep 30. 2016

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group. *J Neurol Neurosurg Psychiatry*. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3. 2016

Mental toughness, sleep disturbances, and physical activity in patients with multiple sclerosis compared to healthy adolescents and young adults.

Sadeghi Bahmani D, Gerber M, Kalak N, Lemola S, Clough PJ, Calabrese P, Shaygannejad V, Pühse U, Holsboer-Trachsler E, Brand S. *Neuropsychiatr Dis Treat*. 2016 Jun 27;12:1571-9. doi: 10.2147/NDT.S111208. eCollection 2016. 2016

The environmental risk factors in multiple sclerosis susceptibility: A case-control study.

Shaygannejad V, Rezaie N, Paknahad Z, Ashtari F, Maghzi H. *Adv Biomed Res*. 2016 Jun 8;5:98. doi: 10.4103/2277-9175.183665. eCollection 2016. 2016

The effect of electronic package on satisfaction in multiple sclerosis patients.

Mohamadirizi S, Shaygannejad V, Mohamadirizi S, Khosrawi S. *Adv Biomed Res*. 2016 May 30;5:89. doi: 10.4103/2277-9175.183143. eCollection 2016. 2016

Co-occurrence of multiple sclerosis and Parkinson disease.

Shaygannejad V, Shirmardi M, Dehghani L, Maghzi H. *Adv Biomed Res*. 2016 Apr 21;5:75. doi: 10.4103/2277-9175.180993. eCollection 2016. 2016

Contribution of different relapse phenotypes to disability in multiple sclerosis.

2016

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermodé A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. *Mult Scler.* 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.

Vasomotor reactivity comparison in multiple sclerosis patients with white matter lesions and nonmultiple sclerosis subjects with white matter lesions in brain magnetic resonance imaging. 2016
Khorvash F, Masaeli A, Shaygannejad V, Saadatnia M. *Adv Biomed Res.* 2016 Feb 8;5:23. doi: 10.4103/2277-9175.175916. eCollection 2016.

Yoga intervention on blood NO in female migraineurs.
Boroujeni MZ, Marandi SM, Esfarjani F, Sattar M, Shaygannejad V, Javanmard SH. *Adv Biomed Res.* 2015 Dec 31;4:259. doi: 10.4103/2277-9175.172995. eCollection 2015.

The Effect of Plasma Exchange on the Expression of FOXP3 and RORC2 in Relapsed Multiple Sclerosis Patients. 2015
Jamshidian A, Kazemi M, Shaygannejad V, Salehi M. *Iran J Immunol.* 2015 Dec;12(4):311-8.

Transocular Doppler and optic nerve sheath diameter monitoring to detect intracranial hypertension.
Karami M, Shirazinejad S, Shaygannejad V, Shirazinejad Z. *Adv Biomed Res.* 2015 Oct 22;4:231. 2015
doi: 10.4103/2277-9175.167900. eCollection 2015.

Psychological well-being in people with multiple sclerosis in an Iranian population.
Dehnavi SR, Heidarian F, Ashtari F, Shaygannejad V. *J Res Med Sci.* 2015 Jun;20(6):535-9. doi: 10.4103/1735-1995.165942. 2015

A comparison of the effects of reflexology and relaxation on pain in women with multiple sclerosis.
Nazari F, Soheili M, Hosseini S, Shaygannejad V. *J Complement Integr Med.* 2016 Mar;13(1):65-71. 2015
doi: 10.1515/jcim-2015-0046.

Preliminary study on patients located at the Kashani/Isfahan Hospital with multiple sclerosis between the years 2011 and 2013. 2015

Tolou-Ghamari Z, Ashtari F, Shaygannejad V, Palizban AA. *Adv Biomed Res.* 2015 Aug 10;4:165. doi: 10.4103/2277-9175.162542. eCollection 2015.

Comparison of emotional and non-emotional word repetitions in patients with aphasia.

Bakhtiyari J, Khatoonabadi SA, Dadgar H, Bakhtiari BM, Khosravizadeh P, Shaygannejad V. *Adv Biomed Res.* 2015 Aug 10;4:164. doi: 10.4103/2277-9175.162540. eCollection 2015. 2015

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.

Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Giuliani G, Barnett M, van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, La Spitaleri D, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, Lechner-Scott J. *PLoS One.* 2015 Jun 5;10(6):e0122686. doi: 10.1371/journal.pone.0122686. eCollection 2015. 2015

Comparing the effects of reflexology and relaxation on fatigue in women with multiple sclerosis.

Nazari F, Shahreza MS, Shaygannejad V, Valiani M. *Iran J Nurs Midwifery Res.* 2015 Mar-Apr;20(2):200-4. 2015

Cytokines gene expression in newly diagnosed multiple sclerosis patients.

Hasheminia SJ, Tolouei S, Zarkesh-Esfahani SH, Shaygannejad V, Shirzad HA, Torabi R, Hashem Zadeh Chaloshutory M. *Iran J Allergy Asthma Immunol.* 2015 Apr;14(2):208-16. 2015

Clinical utility of residual latency in ulnar neuropathy at elbow: Is there any correlation?

Khosrawi S, Dehghan F, Shaygannejad V. *Adv Biomed Res.* 2015 Jan 30;4:21. doi: 10.4103/2277-9175.150386. eCollection 2015. 2015

A Single-subject Study to Examine the Effects of Constrained-induced Aphasia Therapy on Naming Deficit.

Kavian S, Khatoonabadi AR, Ansari NN, Saadati M, Shaygannejad V. *Int J Prev Med.* 2014 Jun;5(6):782-6. 2014

Correlation of midkine serum level with pro- and anti-inflammatory cytokines in multiple sclerosis.

Shaygannejad V, Montazeri S, Jamshidian A, Tahani S, Gharagozloo M, Ashtari F, Vesal S, Hasheminia SJ, Dehghani L. *Iran J Immunol.* 2014 Jun;11(2):134-8. 2014

Toll like receptor 2 and 4 expression in peripheral blood mononuclear cells of multiple sclerosis patients. 2014

Hashemina SJ, Zarkesh-Esfahani SH, Tolouei S, Shaygannejad V, Shirzad H, Hashemzadeh Chaleshtory M. *Iran J Immunol.* 2014 Jun;11(2):74-83.

Preventive Effects of a Three-month Yoga Intervention on Endothelial Function in Patients with Migraine. 2014
Naji-Esfahani H, Zamani M, Marandi SM, Shaygannejad V, Javanmard SH. *Int J Prev Med.* 2014 Apr;5(4):424-9.

Islamic fasting and multiple sclerosis. 2014
Jahromi SR, Sahraian MA, Ashtari F, Ayromlou H, Etemadifar M, Ghaffarpour M, Mohammadianejad E, Nafissi S, Nickseresht A, Shaygannejad V, Togha M, Torabi HR, Ziaie S. *BMC Neurol.* 2014 Mar 22;14:56. doi: 10.1186/1471-2377-14-56.

Multiple sclerosis or neurological manifestations of Celiac disease. 2013
Shaygannejad V, Ghasemi M, Mirmohamadsadeghi M. *Adv Biomed Res.* 2013 Mar 30;2:38. doi: 10.4103/2277-9175.109734. eCollection 2013.

Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon. 2013
Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V. *J Korean Med Sci.* 2013 Dec;28(12):1801-6. doi: 10.3346/jkms.2013.28.12.1801. Epub 2013 Nov 26.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. 2013
Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. *Brain.* 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18.

The psychometric properties of the persian migraine-specific quality of life questionnaire version 2.1 in episodic and chronic migraines. 2013
Zandifar A, Masjedi SS, Haghdoost F, Asgari F, Manouchehri N, Banihashemi M, Najafi MR, Ghorbani A, Zolfaghari B, Gholamrezaei A, Shaygannejad V, Saadatnia M. *ScientificWorldJournal.* 2013 Aug 27;2013:950245. doi: 10.1155/2013/950245. eCollection 2013.

Brain radiation and possible presentation of multiple sclerosis. Shaygannejad V, Zare M, Maghzi H, Emami P. <i>J Res Med Sci.</i> 2013 Mar;18(Suppl 1):S93-5.	2013
Seizure characteristics in multiple sclerosis patients. Shaygannejad V, Ashtari F, Zare M, Ghasemi M, Norouzi R, Maghzi H. <i>J Res Med Sci.</i> 2013 Mar;18(Suppl 1):S74-7.	2013
Oral prednisolone in the treatment of cervical radiculopathy: A randomized placebo controlled trial. Ghasemi M, Masaeli A, Rezvani M, Shaygannejad V, Golabchi K, Norouzi R. <i>J Res Med Sci.</i> 2013 Mar;18(Suppl 1):S43-6.	2013
The value of provocative tests in diagnosis of cervical radiculopathy. Ghasemi M, Golabchi K, Mousavi SA, Asadi B, Rezvani M, Shaygannejad V, Salari M. <i>J Res Med Sci.</i> 2013 Mar;18(Suppl 1):S35-8.	2013
Evaluation of neural gene expression in serum treated embryonic stem cells in Alzheimer's patients. Dehghani L, Hashemi-Beni B, Poorazizi E, Khorvash F, Shaygannejad V, Sedghi M, Vesal S, Meamar R. <i>J Res Med Sci.</i> 2013 Mar;18(Suppl 1):S20-3.	2013
The relation between Vitamin D status with fatigue and depressive symptoms of multiple sclerosis. Ashtari F, Ajalli M, Shaygannejad V, Akbari M, Hovsepian S. <i>J Res Med Sci.</i> 2013 Mar;18(3):193-7.	2013
Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. Jamshidian A, Shaygannejad V, Pourazar A, Zarkesh-Esfahani SH, Gharagozloo M. <i>J Neuroimmunol.</i> 2013 Sep 15;262(1-2):106-12. doi: 10.1016/j.jneuroim.2013.06.007. Epub 2013 Jul 9.	2013
Preliminary investigation of economics issues in hospitalized patients with stroke. Tolou-Ghamari Z, Shaygannejad V, Khorvash F. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S338-42.	2013
Study of type a and B behavior patterns in patients with multiple sclerosis in an Iranian population. Shaygannejad V, Dehnavi SR, Ashtari F, Karimi S, Dehghani L, Meamar R, Tolou-Ghamari Z. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S279-83.	2013
Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital. Tolou-Ghamari Z, Shaygannejad V, Ashtari F. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S274-8.	2013
Olanzapine versus haloperidol: which can control stuttering better?	2013

Shaygannejad V, Khatoonabadi SA, Shafiei B, Ghasemi M, Fatehi F, Meamar R, Dehghani L. *Int J Prev Med.* 2013 May;4(Suppl 2):S270-3.

Can vitamin d suppress endothelial cells apoptosis in multiple sclerosis patients?
Dehghani L, Meamar R, Etemadifar M, Sheshde ZD, Shaygannejad V, Sharifkhah M, Tahani S. *Int J Prev Med.* 2013 May;4(Suppl 2):S211-5. 2013

The effect of pioglitazone on the Alzheimer's disease-induced apoptosis in human umbilical vein endothelial cells. 2013
Dehghani L, Meamar R, Askari G, Khorvash F, Shaygannejad V, Pour AF, Javanmard SH. *Int J Prev Med.* 2013 May;4(Suppl 2):S205-10.

Restless legs syndrome in Iranian multiple sclerosis patients: a case-control study. 2013
Shaygannejad V, Ardestani PE, Ghasemi M, Meamar R. *Int J Prev Med.* 2013 May;4(Suppl 2):S189-93.

The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study. 2013
Ghorbani A, Salari M, Shaygannejad V, Norouzi R. *Int J Prev Med.* 2013 May;4(Suppl 2):S180-4.

What is the Real Fate of Vitamin D in Multiple Sclerosis? 2013
Shaygannejad V, Tolou-Ghamari Z. *Int J Prev Med.* 2013 May;4(Suppl 2):S159-64.

A literature review on the efficacy and safety of botulinum toxin: an injection in post-stroke spasticity. 2013
Ghasemi M, Salari M, Khorvash F, Shaygannejad V. *Int J Prev Med.* 2013 May;4(Suppl 2):S147-58.

Stem cell therapy in stroke: a review literature. 2013
Meamar R, Dehghani L, Ghasemi M, Khorvash F, Shaygannejad V. *Int J Prev Med.* 2013 May;4(Suppl 2):S139-46.

Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. 2013
Shaygannejad V, Janghorbani M, Vaezi A, Haghighi S, Golabchi K, Heshmatipour M. *Neurol Res.* 2013 Jul;35(6):636-41. doi: 10.1179/1743132813Y.0000000200. Epub 2013 Apr 12.

Short-term safety of pulse steroid therapy in multiple sclerosis relapses. 2013
Shaygannejad V, Ashtari F, Alinaghian M, Norouzi R, Salari M, Fatehi F. *Clin Neuropharmacol.* 2013 Jan-Feb;36(1):1-3. doi: 10.1097/WNF.0b013e3182764f91.

Color blindness among multiple sclerosis patients in Isfahan. 2012

Shaygannejad V, Golabchi K, Dehghani A, Ashtari F, Haghghi S, Mirzendehtdel M, Ghasemi M.J Res Med Sci. 2012 Mar;17(3):254-7.

Is the Iranian revolution to blame for the increasing incidence of multiple sclerosis in Iran?

Maghzi AH, Sahraian MA, Shaygannejad V, Minagar A. *Neuroepidemiology*. 2013;40(1):68-9. doi: 2012
10.1159/000341848. Epub 2012 Oct 11.

Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.

Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. *Neurol Res*. 2012 Nov;34(9):854-8. doi: 2012
10.1179/1743132812Y.0000000081. Epub 2012 Sep 12.

Multiple sclerosis in Sistan and Baloochestan, South East Iran.

Maghzi AH, Sahraian MA, Maghzi H, Shaygannejad V. *Clin Neurol Neurosurg*. 2013 Jun;115(6):847- 2012
8. doi: 10.1016/j.clineuro.2012.08.014. Epub 2012 Aug 22.

Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.

Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. *Mult Scler Int*. 2012;2012:452541. doi: 2012
10.1155/2012/452541. Epub 2012 Apr 11.

Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.

Basiri K, Etemadifar M, Derakhshan F, Ashtari F, Shaygannejad V, Fatehi Z, Maghzi AH, Fatehi F. *Acta Med Iran*. 2012;50(2):97-100. 2012

The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: A randomized single-blind clinical trial.

Tajmirriahi M, Sohelipour M, Basiri K, Shaygannejad V, Ghorbani A, Saadatnia M. *Iran J Neurol*. 2012;11(1):21-4. 2012

Optical coherence tomography versus visual evoked potential in multiple sclerosis patients.

Fatehi F, Shaygannejad V, Mehr LK, Dehghani A. *Iran J Neurol*. 2012;11(1):12-5. 2012

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.

Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, 2012

Kee F, Gray O, Butzkueven H; MSBase Study Group. *J Neurol Neurosurg Psychiatry*. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28.

Myasthenia gravis as a presenting feature in a patient with lung cancer: A case report. 2011
Shaygannejad V, Ghasemi M, Rajaei Z. *J Res Med Sci*. 2011 Feb;16(2):229-32.

A Comparative Study of 25 (OH) Vitamin D Serum Levels in Patients with Multiple Sclerosis and Control Group in Isfahan, Iran. 2010
Shaygannejad V, Golabchi K, Haghighi S, Dehghan H, Moshayedi A. *Int J Prev Med*. 2010 Summer;1(3):195-201.

Does early-onset multiple sclerosis differ from adult-onset form in Iranian people. 2010
Ashtari F, Shaygannejad V, Farajzadegan Z, Amin A. *J Res Med Sci*. 2010 Mar;15(2):94-9.

Is Chiari malformation a cause of systemic hypertension and sinus bradycardia? A case report and literature review. 2010
Ghasemi M, Golabchi K, Shaygannejad V, Rezvani M. *J Res Med Sci*. 2011 Jan;16(1):115-8.

Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial. 2010
Shaygannejad V, Janghorbani M, Savoj MR, Ashtari F. *Neurol Res*. 2010 Nov;32(9):981-5. doi: 10.1179/016164110X12656393664964. Epub 2010 Mar 10.

Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis? 2009
Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A. *Neurol Neurochir Pol*. 2009 Sep-Oct;43(5):428-32.

Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. 2009
Chitsaz A, Janghorbani M, Shaygannejad V, Ashtari F, Heshmatipour M, Freeman J. *Clin J Pain*. 2009 May;25(4):281-5. doi: 10.1097/AJP.0b013e318190862b.

Short-term effects of prolonged fasting on multiple sclerosis. 2009
Saadatnia M, Etemadifar M, Fatehi F, Ashtari F, Shaygannejad V, Chitsaz A, Maghzi AH. *Eur Neurol*. 2009;61(4):230-2. doi: 10.1159/000197108. Epub 2009 Jan 29.

Effects of rivastigmine on memory and cognition in multiple sclerosis. 2008
Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. *Can J Neurol Sci*. 2008 Sep;35(4):476-81. doi: 10.1017/s0317167100009148.

Prevalence of multiple sclerosis in Isfahan, Iran.

Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. *Neuroepidemiology*. 2006;27(1):39-44. 2006
doi: 10.1159/000094235. Epub 2006 Jun 27.

Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized
blinded crossover study.

Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. *Headache*. 2006
Apr;46(4):642-8. doi: 10.1111/j.1526-4610.2006.00413. x. 2006

Theses

More than 65 theses with neurological residents, medical students and also with PhD by research students.

PRESENTATIONS AND POSTER SESSIONS

I have presented aspects of my research in the form of both oral and poster communications at various major national and international conferences which the papers are given in previous section.

PATENTS

-

RESEARCH INTERESTS

Neurology, Neurosciences

TEACHING INTERESTS

Multiple Sclerosis

PROFESSIONAL MEMBERSHIPS

Faculty member of Isfahan University of Medical Sciences

Head of Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences

Head of MS Clinic in Isfahan Kashani Hospital, Isfahan University of Medical Sciences

Member of MSBase International Registry

Member of Iranian Multiple Sclerosis Society

EXTRA CURRICULAR ACTIVITIES

Editorial Board member: *Advanced Biomedical Research Journal*

Journal reviewer:

1. Journal of Research in Medical Sciences
2. International Journal of Preventive Medicine
3. Advanced Biomedical Research Journal
4. ARYA Atherosclerosis
5. Iranian journal of neurology
6. National Institute for Medical Research Development (NIMAD)

Grant reviewer: International Journal of Preventive Medicine